Phaseline

Targets › LRAT

LRAT (Lecithin retinol acyltransferase): drug programs, companies and trials

1 program from 1 company in 3 trials: 2 Phase 2, 1 Phase 3; Ophthalmology; next expected readout Jun 2028.

Transfers the acyl group from the sn-1 position of phosphatidylcholine to all-trans retinol, producing all-trans retinyl esters. Retinyl esters are storage forms of vitamin A (Probable). (UniProt, O95237)

Open in Phaseline: the race on LRAT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Alkeus PharmaceuticalsALK-001
Deuterated vitamin A analog that slows production of lipofuscin and related retinoid bypro
LRATPhase 3Stargardt DiseaseJun 2028

Conditions

Stargardt Disease (3)

Modalities

small molecule (1)

Companies

Alkeus Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.